LENZ Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate Highlights
LENZ Therapeutics (NASDAQ: LENZ) has reported its Q4 and full year 2024 financial results, highlighting significant progress toward the potential approval of LNZ100 for presbyopia treatment. The FDA has set a PDUFA target action date of August 8, 2025, with no Advisory Committee Meeting planned.
Key financial metrics include:
- Cash position of $209.1 million as of December 31, 2024
- Q4 2024 R&D expenses decreased to $5.9 million from $19.5 million in Q4 2023
- Q4 2024 SG&A expenses increased to $9.4 million from $5.5 million in Q4 2023
- Q4 2024 net loss of $12.7 million ($0.46 per share)
The company has completed its mid-cycle review with the FDA and initiated production for commercial launch. Phase 3 study results in China showed positive outcomes, with 74% of patients achieving three-lines or greater improvement at 3 hours. Commercial preparations are advancing with expanded infrastructure and key sales force leadership appointments.
LENZ Therapeutics (NASDAQ: LENZ) ha riportato i risultati finanziari del quarto trimestre e dell'intero anno 2024, evidenziando progressi significativi verso la potenziale approvazione di LNZ100 per il trattamento della presbiopia. La FDA ha fissato una data obiettivo per l'azione PDUFA al 8 agosto 2025, senza alcun incontro del Comitato Consultivo previsto.
I principali indicatori finanziari includono:
- Posizione di cassa di 209,1 milioni di dollari al 31 dicembre 2024
- Le spese per R&S del Q4 2024 sono diminuite a 5,9 milioni di dollari rispetto ai 19,5 milioni di dollari del Q4 2023
- Le spese SG&A del Q4 2024 sono aumentate a 9,4 milioni di dollari rispetto ai 5,5 milioni di dollari del Q4 2023
- Perdita netta del Q4 2024 di 12,7 milioni di dollari (0,46 dollari per azione)
L'azienda ha completato la revisione di metà ciclo con la FDA e ha avviato la produzione per il lancio commerciale. I risultati dello studio di Fase 3 in Cina hanno mostrato esiti positivi, con il 74% dei pazienti che ha raggiunto un miglioramento di tre linee o più dopo 3 ore. I preparativi commerciali stanno progredendo con un'infrastruttura ampliata e importanti nomine nella leadership della forza vendita.
LENZ Therapeutics (NASDAQ: LENZ) ha reportado sus resultados financieros del cuarto trimestre y del año completo 2024, destacando un progreso significativo hacia la posible aprobación de LNZ100 para el tratamiento de la presbicia. La FDA ha establecido una fecha objetivo de acción PDUFA para el 8 de agosto de 2025, sin ninguna reunión del Comité Asesor programada.
Los principales indicadores financieros incluyen:
- Posición de efectivo de 209,1 millones de dólares al 31 de diciembre de 2024
- Los gastos en I+D del Q4 2024 disminuyeron a 5,9 millones de dólares desde 19,5 millones de dólares en el Q4 2023
- Los gastos SG&A del Q4 2024 aumentaron a 9,4 millones de dólares desde 5,5 millones de dólares en el Q4 2023
- Pérdida neta del Q4 2024 de 12,7 millones de dólares (0,46 dólares por acción)
La empresa ha completado su revisión de medio ciclo con la FDA e iniciado la producción para el lanzamiento comercial. Los resultados del estudio de Fase 3 en China mostraron resultados positivos, con el 74% de los pacientes logrando una mejora de tres líneas o más a las 3 horas. Los preparativos comerciales están avanzando con una infraestructura ampliada y nombramientos clave en el liderazgo de la fuerza de ventas.
LENZ Therapeutics (NASDAQ: LENZ)는 2024년 4분기 및 전체 연도 재무 결과를 발표하며, 노안 치료를 위한 LNZ100의 잠재적 승인을 향한 중요한 진전을 강조했습니다. FDA는 2025년 8월 8일에 PDUFA 목표 조치 날짜를 설정했으며, 자문 위원회 회의는 계획되어 있지 않습니다.
주요 재무 지표는 다음과 같습니다:
- 2024년 12월 31일 기준 현금 보유액 2억 9백 10만 달러
- 2024년 4분기 연구개발(R&D) 비용은 5.9백만 달러로 2023년 4분기 19.5백만 달러에서 감소했습니다.
- 2024년 4분기 판매 및 관리(SG&A) 비용은 5.5백만 달러에서 9.4백만 달러로 증가했습니다.
- 2024년 4분기 순손실은 1,270만 달러(주당 0.46달러)입니다.
회사는 FDA와의 중간 검토를 완료하고 상업적 출시를 위한 생산을 시작했습니다. 중국에서의 3상 연구 결과는 긍정적인 결과를 보여주었으며, 환자의 74%가 3시간 이내에 3라인 이상의 개선을 달성했습니다. 상업적 준비는 확장된 인프라와 주요 영업 리더십 임명으로 진행되고 있습니다.
LENZ Therapeutics (NASDAQ: LENZ) a publié ses résultats financiers pour le quatrième trimestre et l'année complète 2024, mettant en évidence des progrès significatifs vers l'approbation potentielle de LNZ100 pour le traitement de la presbytie. La FDA a fixé une date d'action cible PDUFA au 8 août 2025, sans réunion du comité consultatif prévue.
Les principaux indicateurs financiers incluent :
- Position de trésorerie de 209,1 millions de dollars au 31 décembre 2024
- Les dépenses de R&D du T4 2024 ont diminué à 5,9 millions de dollars contre 19,5 millions de dollars au T4 2023
- Les dépenses SG&A du T4 2024 ont augmenté à 9,4 millions de dollars contre 5,5 millions de dollars au T4 2023
- Perte nette du T4 2024 de 12,7 millions de dollars (0,46 dollar par action)
L'entreprise a terminé son examen de mi-cycle avec la FDA et a lancé la production pour le lancement commercial. Les résultats de l'étude de phase 3 en Chine ont montré des résultats positifs, avec 74 % des patients atteignant une amélioration de trois lignes ou plus en 3 heures. Les préparatifs commerciaux avancent avec une infrastructure élargie et des nominations clés dans la direction des ventes.
LENZ Therapeutics (NASDAQ: LENZ) hat seine Finanzzahlen für das vierte Quartal und das gesamte Jahr 2024 veröffentlicht und dabei signifikante Fortschritte in Richtung der potenziellen Genehmigung von LNZ100 zur Behandlung von Presbyopie hervorgehoben. Die FDA hat ein Zieltermin für die PDUFA-Aktion auf den 8. August 2025 festgelegt, ohne dass ein Treffen des Beratungsausschusses geplant ist.
Wichtige Finanzkennzahlen umfassen:
- Liquiditätsposition von 209,1 Millionen Dollar zum 31. Dezember 2024
- Forschungs- und Entwicklungskosten (F&E) im Q4 2024 sanken auf 5,9 Millionen Dollar von 19,5 Millionen Dollar im Q4 2023
- Vertriebskosten und allgemeine Verwaltungskosten (SG&A) im Q4 2024 stiegen auf 9,4 Millionen Dollar von 5,5 Millionen Dollar im Q4 2023
- Nettoverlust im Q4 2024 von 12,7 Millionen Dollar (0,46 Dollar pro Aktie)
Das Unternehmen hat seine Mid-Cycle-Überprüfung mit der FDA abgeschlossen und die Produktion für den kommerziellen Launch eingeleitet. Die Ergebnisse der Phase-3-Studie in China zeigten positive Ergebnisse, wobei 74% der Patienten innerhalb von 3 Stunden eine Verbesserung um drei Linien oder mehr erzielten. Die kommerziellen Vorbereitungen schreiten mit einer erweiterten Infrastruktur und wichtigen Ernennungen in der Vertriebsführung voran.
- Strong cash position of $209.1 million expected to fund operations through commercial launch
- Significant reduction in R&D expenses (76% decrease in Q4 2024 vs Q4 2023)
- Positive Phase 3 results in China with 74% efficacy rate
- FDA mid-cycle review completed with no significant issues identified
- Commercial infrastructure expansion progressing with key sales leadership appointments
- Increased SG&A expenses (71% increase in Q4 2024 vs Q4 2023)
- Continued net losses ($12.7 million in Q4 2024)
- Pre-revenue company dependent on FDA approval for commercialization
Insights
LENZ Therapeutics' Q4 and full-year 2024 results showcase a company executing effectively on its regulatory and pre-commercial strategies for LNZ100, its lead presbyopia candidate. The FDA's acceptance of their NDA with a PDUFA date of August 8, 2025, represents a critical regulatory milestone. Notably, the mid-cycle review revealed no significant issues, and the FDA has confirmed no plans for an Advisory Committee meeting - both positive signals for potential approval.
The company's financial position appears solid with $209.1 million in cash and equivalents, which management projects will sustain operations through commercial launch to positive cash flow. The 49.9% reduction in R&D expenses (from $59.5M to $29.8M year-over-year) reflects the successful completion of the pivotal CLARITY trial, while the 123% increase in SG&A expenses (from $12.9M to $28.8M) demonstrates appropriate investment in commercial infrastructure.
The target market is substantial, with an estimated 128 million people with presbyopia in the US alone. The positive China Phase 3 data, showing 74% of patients achieving three-line improvement in near vision, further validates LNZ100's efficacy profile. The strategic hiring of regional sales directors and district managers signals the company is building appropriate commercial capacity for a potential Q4 2025 launch.
While LENZ remains pre-revenue with a net loss of $49.8 million for 2024, the decreasing quarterly burn rate and focused pre-commercial investments reflect disciplined capital allocation ahead of a potentially transformative product launch.
LENZ Therapeutics' financial results show a company effectively managing its transition from clinical to commercial stage. The $209.1 million cash position provides a critical runway through potential FDA approval and commercial launch, eliminating near-term financing risk. This represents approximately 31% of the company's market cap of $668.8 million, providing a meaningful cash buffer.
The $49.8 million annual net loss ($2.34 per share) marks a 28.9% improvement over 2023's $70.0 million loss, reflecting prudent resource allocation. Q4's narrowed loss of $12.7 million ($0.46 per share) versus $23.7 million in Q4 2023 shows continued expense management. The R&D expense reduction to $29.8 million (from $59.5 million) demonstrates the natural evolution toward commercialization, while the increased SG&A spend of $28.8 million (up from $12.9 million) reflects necessary commercial infrastructure investments.
With the ECP education campaign generating over 2 million impressions and commercial leadership now in place, LENZ is methodically deploying capital toward market preparation. The strategic timing of expenses is important - completing necessary investments before potential Q4 2025 product availability while maintaining sufficient cash to reach positive operating cash flow.
For investors, the key financial inflection point remains the August 8, 2025 PDUFA date. Successful approval would position LENZ to address the substantial presbyopia market with potential for significant revenue generation beginning in late 2025, transforming the company's financial profile from cash-burning to potentially cash-generating.
New Drug Application (NDA) for LNZ100 for treatment of presbyopia on track for PDUFA target action date of August 8, 2025
Upon FDA approval, commercial launch activities to commence immediately with LNZ100 product availability anticipated in the fourth quarter of 2025
Cash, cash equivalents and marketable securities of
Company to host a conference call today at 4:30 p.m. EST
SAN DIEGO, March 19, 2025 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (Nasdaq: LENZ or “LENZ” or the “Company”), a pre-commercial stage biopharmaceutical company focused on the development and commercialization of the first and only aceclidine-based eye drop to improve near vision in people with presbyopia, today reported financial results for the fourth quarter and full year ended December 31, 2024, and recent corporate highlights.
“This year has been an extremely successful year for LENZ, and we have continued to make progress in the fourth quarter and recent period as we move closer to the potential approval and launch of LNZ100 in the United States,” said Eef Schimmelpennink, President and Chief Executive Officer of LENZ Therapeutics. “I am very pleased with the advancements made by our regulatory team with the FDA, having recently completed our mid-cycle review, which led to our manufacturing operations team initiating production to support our potential commercial launch. Importantly, the recent period has been highlighted by the focus and execution of our medical affairs team, continuing to educate the ECP community on the benefits of a pupil-selective, ciliary-body sparing miotic for the treatment of presbyopia, in addition to impressive pre-commercial planning efforts as we near completion of our full commercial infrastructure and finalized our branding creative. We look forward to highlighting much of this recent progress and more at our upcoming Commercial Day on April 15th.”
Fourth Quarter 2024 and Recent Corporate Highlights
Announced New Drug Application (NDA) acceptance by the U.S. Food and Drug Administration (FDA) for LNZ100 as a treatment for presbyopia. In October 2024, the Company announced that the FDA accepted the NDA for LNZ100 for the treatment of presbyopia, a condition that impacts an estimated 1.8 billion people globally and 128 million people in the United States. The Company previously announced the submission of its NDA in August 2024. The FDA has assigned a Prescription Drug User Fee Act (PDUFA) target action date of August 8, 2025 for LNZ100, and noted it is not planning to hold an Advisory Committee Meeting to discuss this application. In January 2025, the mid-cycle review meeting and communications were completed, noting no significant review issues. In the mid-cycle review communications, the FDA reiterated it had no plans to request an Advisory Committee Meeting. The NDA submission for the treatment of presbyopia is supported by positive data from the pivotal Phase 3 CLARITY study. Aceclidine is a new chemical entity in the United States and is not approved for the treatment of presbyopia in any country.
Pre-launch U.S. commercial planning advanced in preparation for potential August 2025 approval. The Commercial team advanced its commercial readiness for LNZ100 for the treatment of presbyopia as the Company progressed towards the August 8, 2025 PDUFA target action date. Now approaching its first anniversary date of the EYEAMSELECTIVE unbranded campaign, the awareness of the Eye Care Professional (ECP) community on the importance of a pupil-selective and ciliary-body sparing miotic continued to grow, with over 2 million digital campaign impressions targeting over 30,000 ECPs. In the fourth quarter 2024 and recent period, the Company further expanded its commercial infrastructure and hired key sales force leadership including Regional Sales Directors and all District Managers, adding substantial commercial eye care and pharmaceutical sales experience.
CORXEL and LENZ Therapeutics announced positive topline data from Phase 3 study in China for the treatment of presbyopia. In October 2024, CORXEL and the Company announced topline data from the Phase 3 safety and efficacy study in China. In the Phase 3 study, LNZ100 (
LENZ to host Commercial Day on April 15, 2025. The Company will host a Commercial Day to highlight the commercialization strategy and progress towards the potential approval of LNZ100 for the treatment of presbyopia. The event will take place on Tuesday, April 15, 2025, from 2:00 p.m. – 4:00 p.m. EST. The event will include presentations by management to feature key updates as the Company approaches the potential approval and launch of LNZ100, including commercialization strategies, supply chain and product distribution readiness and perspectives from Key Opinion Leader and ECPs. A live audio webcast of the presentation will be available through the link here and on the Events section of the Investor Relations page of the LENZ Therapeutics website at www.LENZ-tx.com.
Financial Results for Three Months and Year Ended December 31, 2024
Cash Position: Cash, cash equivalents and marketable securities were
Research and Development (R&D) Expenses: R&D expenses decreased to
Selling, General and Administrative (SG&A) Expenses: SG&A expenses were
Net Loss: Net loss for the three months ended December 31, 2024, was
Conference Call Information
The Company will host a conference call and webcast today, Wednesday, March 19, 2025, at 4:30 p.m. EST. To participate in the conference call via telephone, dial (800) 715-9871 (Domestic) or (646) 307-1963 (International) and enter code 9147301. The live webcast can be accessed here and on the LENZ Therapeutics website at www.LENZ-tx.com in the Investors & Media section. A replay of the webcast will be available on the Company’s website for 30 days following the event.
About LENZ Therapeutics
LENZ Therapeutics is a pre-commercial biopharmaceutical company focused on the development and commercialization of the first and only aceclidine-based eye drop to improve near vision in patients with presbyopia. LENZ’s product candidate, LNZ100 is a preservative-free, single-use, once-daily eye drop containing aceclidine. LNZ100 was evaluated in the registration-enabling Phase 3 CLARITY study as a potential therapy for the treatment of presbyopia, a condition impacting an estimated 1.8 billion people globally and 128 million people in the United States. The U.S. Food and Drug Administration (FDA) has assigned a Prescription Drug User Fee Act (PDUFA) target action date of August 8, 2025 for LNZ100. LENZ is committed to commercializing an ideal pharmaceutical presbyopia solution that enhances vision for “all eyes, all day”. LENZ is headquartered in San Diego, California. For more information, visit: LENZ-Tx.com.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of federal securities laws. You can identify forward-looking statements by words such as “may,” “will,” “could,” “can,” “would,” “should,” “expect,” “intend,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “project,” “potential,” “poised,” “continue,” “ongoing” or the negative of these terms or other comparable terminology, but not all forward-looking statements will contain these words. Forward-looking statements in this press release include, but are not limited to, statements regarding the review and potential approval of our NDA by FDA for the potential regulatory approval; approval and commercialization of LNZ100 as a global therapy; our plans relating to commercialization, including engagement with key opinion leaders and eye care professionals and the development of commercial capabilities; the size of the market opportunity for LNZ100; the beneficial characteristics of LNZ100 and its expected impact on presbyopes; our plans to host a Commercial Day and the subject matter to be discussed at such event; and expectations regarding shareholder value creation. These statements are based on numerous assumptions concerning the development of LENZ’s product candidates and target markets and involve substantial risks, uncertainties and other factors that may cause actual results, levels of activity, performance or achievement to be materially different from the information expressed or implied by these forward-looking statements, including those risk factors described in the section titled “Risk Factors” in our Annual Report on Form 10-K to be filed for the year ended December 31, 2024 and our subsequent filings with the SEC. We cannot assure you that the forward-looking statements in this press release or the assumptions upon which they are based will prove to be accurate. The forward-looking statements in this press release are as of the date of this press release. Except as otherwise required by applicable law, LENZ disclaims any duty to update any forward-looking statements. You should, therefore, not rely on these forward-looking statements as representing our views as of any date subsequent to the date of this press release.
Contact:
Dan Chevallard
LENZ Therapeutics
IR@LENZ-Tx.com
LENZ Therapeutics, Inc. Selected Consolidated Balance Sheets Highlights (in thousands) | ||||||
December 31, | ||||||
2024 | 2023 | |||||
Cash and cash equivalents | $ | 20,158 | $ | 35,140 | ||
Marketable securities | 188,872 | 30,654 | ||||
Total assets | 215,304 | 70,376 | ||||
Total liabilities | 11,220 | 19,698 | ||||
Total stockholders’ equity (deficit) | 204,084 | (92,712 | ) |
LENZ Therapeutics, Inc. Consolidated Statement of Operations and Comprehensive Loss (in thousands, except share and per share data) | |||||||||||||||
Three Months Ended December 31, | Year Ended December 31, | ||||||||||||||
2024 | 2023 | 2024 | 2023 | ||||||||||||
Operating expenses: | |||||||||||||||
Research and development | $ | 5,868 | $ | 19,536 | $ | 29,801 | $ | 59,504 | |||||||
Selling, general and administrative | 9,357 | 5,453 | 28,809 | 12,925 | |||||||||||
Total operating expenses | 15,225 | 24,989 | 58,610 | 72,429 | |||||||||||
Loss from operations | (15,225 | ) | (24,989 | ) | (58,610 | ) | (72,429 | ) | |||||||
Other income: | |||||||||||||||
Other income | 8 | 267 | 289 | 93 | |||||||||||
Interest income | 2,566 | 851 | 8,553 | 2,189 | |||||||||||
Total other income, net | 2,574 | 1,118 | 8,842 | 2,282 | |||||||||||
Net loss before income taxes | $ | (12,651 | ) | $ | (23,871 | ) | $ | (49,768 | ) | $ | (70,147 | ) | |||
Income tax expense (benefit) | 1 | (179 | ) | 1 | (179 | ) | |||||||||
Net loss | (12,652 | ) | (23,692 | ) | (49,769 | ) | (69,968 | ) | |||||||
Other comprehensive income (loss): | |||||||||||||||
Unrealized (loss) gain on marketable securities | (327 | ) | 11 | 190 | 6 | ||||||||||
Comprehensive loss | $ | (12,979 | ) | $ | (23,681 | ) | $ | (49,579 | ) | $ | (69,962 | ) | |||
Net loss per share, basic and diluted | $ | (0.46 | ) | $ | (12.04 | ) | $ | (2.34 | ) | $ | (35.71 | ) | |||
Weighted-average common shares outstanding, basic and diluted | 27,492,616 | 1,967,434 | 21,281,038 | 1,959,091 |
